The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects. Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness. Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair mechanisms and represent a valid target for new therapies. Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death. In phase II clinical trials, including patients with advanced castration-resistant PC, olaparib seems to be efficacious and well tolerated. Waiting for randomized phase III trials, olaparib should be considered as a promising treatment option for PC.

De Felice, F., Tombolini, V., Marampon, F., Musella, A., Marchetti, C., Defective DNA repair mechanisms in prostate cancer: Impact of olaparib, <<DRUG DESIGN, DEVELOPMENT AND THERAPY>>, n/a; 11 (N/A): 547-552. [doi:10.2147/DDDT.S110264] [http://hdl.handle.net/10807/203886]

Defective DNA repair mechanisms in prostate cancer: Impact of olaparib

Marchetti, Claudia
2017

Abstract

The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects. Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness. Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair mechanisms and represent a valid target for new therapies. Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death. In phase II clinical trials, including patients with advanced castration-resistant PC, olaparib seems to be efficacious and well tolerated. Waiting for randomized phase III trials, olaparib should be considered as a promising treatment option for PC.
2017
Inglese
De Felice, F., Tombolini, V., Marampon, F., Musella, A., Marchetti, C., Defective DNA repair mechanisms in prostate cancer: Impact of olaparib, <<DRUG DESIGN, DEVELOPMENT AND THERAPY>>, n/a; 11 (N/A): 547-552. [doi:10.2147/DDDT.S110264] [http://hdl.handle.net/10807/203886]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/203886
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 25
social impact